<?xml version="1.0" encoding="UTF-8"?>
<ref id="B48">
 <label>48.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhu</surname>
    <given-names>FC</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>YH</given-names>
   </name>
   <name>
    <surname>Guan</surname>
    <given-names>XH</given-names>
   </name>
   <name>
    <surname>Hou</surname>
    <given-names>LH</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>WJ</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>JX</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title>. 
  <source>Lancet</source>. (
  <year>2020</year>) 
  <volume>395</volume>:
  <fpage>1845</fpage>â€“
  <lpage>54</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id>
  <?supplied-pmid 32450106?>
  <pub-id pub-id-type="pmid">32450106</pub-id>
 </mixed-citation>
</ref>
